GPR56/ADGRG1 Inhibits Mesenchymal Differentiation and Radioresistance in Glioblastoma by Moreno, Marta et al.
  
 University of Groningen
GPR56/ADGRG1 Inhibits Mesenchymal Differentiation and Radioresistance in Glioblastoma
Moreno, Marta; Pedrosa, Leire; Pare, Laia; Pineda, Estela; Bejarano, Leire; Martinez,






IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from
it. Please check the document version below.
Document Version
Publisher's PDF, also known as Version of record
Publication date:
2017
Link to publication in University of Groningen/UMCG research database
Citation for published version (APA):
Moreno, M., Pedrosa, L., Pare, L., Pineda, E., Bejarano, L., Martinez, J., ... de la Iglesia, N. (2017).
GPR56/ADGRG1 Inhibits Mesenchymal Differentiation and Radioresistance in Glioblastoma. Cell reports,
21(8), 2183-2197. https://doi.org/10.1016/j.celrep.2017.10.083
Copyright
Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the
author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).
Take-down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately
and investigate your claim.
Downloaded from the University of Groningen/UMCG research database (Pure): http://www.rug.nl/research/portal. For technical reasons the






















1696Skin accumulation of advanced glycation end products is
increased in patients with an abdominal aortic aneurysmJeltje Boersema, BSc,a Lisanne C. de Vos, MD, PhD,a Thera P. Links, MD, PhD,b Douwe J. Mulder, MD, PhD,a
Andries J. Smit, MD, PhD,a Clark J. Zeebregts, MD, PhD,c and Joop D. Lefrandt, MD, PhD,a Groningen,
The NetherlandsABSTRACT
Objective: Advanced glycation end products (AGEs) are implicated in the pathogenesis of cardiovascular disease.
Accumulation of AGEs is driven by oxidative or glycemic stress and can be assessed by skin autoﬂuorescence (SAF). SAF is
increased in patients with peripheral artery disease (PAD) and independently associated with mortality and major
adverse cardiovascular events in these patients. PAD and abdominal aortic aneurysm (AAA) share several risk factors.
Inﬂammation is an important process in AAA formation and increases levels of oxidative stress. We therefore hypothe-
sized that SAF would be increased in AAA patients compared with controls.
Methods: A case-control study was performed in 248 AAA patients and 124 controls without AAA or PADmatched for age
and presence of diabetes mellitus. SAF was noninvasively assessed with the AGE Reader (Diagnoptics Technologies BV,
Groningen, The Netherlands).
Results: SAF was higher in AAA patients than in controls: 2.89 6 0.63 vs 2.68 6 0.63 arbitrary units (P ¼ .003). PAD
comorbidity was associated with increased SAF within the AAA patient group (P ¼ .01). After correction for known factors
inﬂuencing SAF (age, current smoking, hypertension, and estimated glomerular ﬁltration rate), PAD comorbidity
remained an independent determinant of SAF. Logistic regression analysis of the total cohort showed an unadjusted
odds ratio (OR) of 1.74 (95% conﬁdence interval [CI], 1.20-2.51) for the presence of AAA with each unit increase of SAF and
an adjusted OR of 1.78 (95% CI, 1.22-2.60) after correction for cardiovascular comorbidity (cerebrovascular disease and
coronary artery disease). After additional correction for sex, current smoking, hypertension, and use of lipid-lowering
drugs, this signiﬁcance was lost (adjusted OR, 1.53; 95% CI, 0.94-2.48).
Conclusions: Skin accumulation of AGEs, measured by SAF, is increased in patients with AAA compared with controls
without AAA or PAD, independent of the presence of coronary artery disease and cerebrovascular disease. In AAA pa-
tients, SAF is closely associated with the presence of PAD and cardiovascular risk factors. (J Vasc Surg 2017;66:1696-703.)An abdominal aortic aneurysm (AAA) is characterized
by enlargement of the aorta as a consequence of patho-
physiological changes in the aortic vascular wall,
including inﬂammation, smooth muscle cell apoptosis,
and proteolysis of elastin and collagen in the tunica
media.1 Most AAAs are discovered as an incidental
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Advanced glycation end products (AGEs) are formed by
nonenzymatic reactions on reducing sugars and proteins
and have two potentially harmful effects.4 First, forma-
tion of cross-links contributes to stiffening of the myocar-
dium and arteries.5 Second, interaction with the receptor
for AGEs induces inﬂammatory responses through
activation of nuclear factor-kB and consecutive release
of proinﬂammatory cytokines.4
Assessment of skin AGEs can be performed with a
noninvasive technique called skin autoﬂuorescence
(SAF).6 The estimated turnover time of skin collagen is
15 years; thus, skin AGEs and SAF represent a long-term
metabolic memory.7 In addition, SAF is positively related
to AGE levels in cardiac tissue and venous bypass graft
material, both vascular tissues with also a typical slow
turnover.8,9
Although the formation and accumulation of AGEs in
long-lived tissues occurs physiologically with aging, this
formation is enhanced in conditions associated with
hyperglycemia or oxidative stress such as diabetes melli-
tus (DM), autoimmune disease, renal insufﬁciency, and
atherosclerosis.4 As a result, SAF is increased in patients
with these conditions compared with controls,10-13 and
increased SAF is also associated with major adverse
ARTICLE HIGHLIGHTS
d Type of Research: Single-center prospective case-
controlled study
d Take Home Message: Skin accumulation of
advanced glycation end products as measured by
skin autoﬂuorescence was increased in 248 patients
with abdominal aortic aneurysm compared with 124
matched controls.
d Recommendation: This study suggests that using
skin autoﬂuorescence to measure advanced glyca-
tion end products may be a useful in the detection
of patients with abdominal aortic aneurysm.
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Volume 66, Number 6cardiovascular events in patients with DM, myocardial
infarction, and peripheral artery disease (PAD).14-17
PAD and AAA disease share several risk factors and
are frequently found in the same patient. Inﬂammation
is an important pathway of AAA formation, mediating
elastin and collagen degradation by proteases derived
from inﬂammatory cells.18 This led us to hypothesize
that SAF, as a measure of skin AGEs, would be
increased in patients with an AAA; therefore, the aim
of this study was to compare SAF levels in AAA pa-
tients and controls. We also investigated whether SAF
is associated with the presence of AAA after correction
for cardiovascular risk factors, such as smoking, and
cardiovascular comorbidity, expressed by a history of
cerebrovascular disease (CVD) or coronary artery dis-
ease (CAD).
METHODS
Study population. We performed a case-control study.
AAA patients were recruited from the vascular surgery
outpatient clinic at the University Medical Center
Groningen (UMCG), The Netherlands, between 2007
and 2011. Patients at least 18 years of age with a
conﬁrmed AAA were eligible to participate. AAA was
ascertained by evidence of an enlarged diameter of
the aorta of $30 mm on ultrasound imaging, mag-
netic resonance angiography, or computed tomogra-
phy angiography. In case of an emergency or elective
repair without available medical imaging reports, sur-
gical reports or referral letters were used to conﬁrm
the diagnosis.
AAA patients and controls were matched 2:1 by age and
presence of DM (Fig 1). Controls were selected from
earlier studies. Diabetic controls were selected from a
cohort (n ¼ 973) from the diabetes outpatient clinic,
Zwolle, The Netherlands.11 The nondiabetic control group
consisted of patients admitted to the UMCG for surgical
interventions (n ¼ 231) unrelated to cardiovascular
disease and of patients who visited the vascular surgery
outpatient clinic in the UMCG (n ¼ 121), mostly because
of varicose veins or carotid artery stenosis, who had no
history or symptoms of AAA or PAD.12,13
Exclusion criteria for AAA patients and controls were
sepsis, recent myocardial infarction or stroke, deﬁned as
an event #3 months before recruitment, renal replace-
ment therapy or end-stage renal disease (estimated
glomerular ﬁltration rate [eGFR] <15 mL/min/1.73m2),
solid organ transplantation, or active cancer. AAA
patients with a mycotic or inﬂammatory aneurysm or a
history of connective tissue disease were excluded.
Control patients with a history or symptoms of AAA or
PAD were also excluded.
All participating patients gave informed consent. The
study was approved by the local Institutional Review
Board and complied with the principles of the Declara-
tion of Helsinki.Data collection. Traditional cardiovascular risk factors
were prospectively assessed, including current smoking
status, body mass index, presence of DM, hypertension,
eGFR, and use of lipid-lowering, glucose-lowering, or
anticoagulant drugs. eGFR was calculated from the
serum creatinine level using the Modiﬁcation of Diet in
Renal Disease formula.19 Hypertension was deﬁned as a
systolic blood pressure $140 mm Hg, a diastolic blood
pressure $90 mm Hg, or the use of blood pressure-
lowering drugs. Lipid-lowering therapy was deﬁned as
the use of statins, ezetimibe, or ﬁbrates. For glucose-
lowering therapy, the use of metformin, dipeptidyl
peptidase 4 inhibitors, repaglinide, sulfonylurea de-
rivatives, pioglitazone, glucagon-like peptide 1 receptor
agonists, sodium-glucose cotransporter 2 inhibitors, and
insulin was assessed. Anticoagulant therapy was deﬁned
as the use of anticoagulant or antiplatelet therapy.
History of cardiovascular comorbidity was retrieved
from medical records and divided into CAD, CVD, and
PAD. CAD was deﬁned as a history of angina pectoris,
myocardial infarction, percutaneous coronary interven-
tion, or coronary artery bypass graft. CVD was deﬁned
as a history of stroke, transient ischemic attack, carotid
endarterectomy, or carotid stenting. PAD was deﬁned
as a resting ankle-brachial index #0.90 combined with
conﬁrmation of obstructive disease on computed to-
mography angiography, magnetic resonance angiog-
raphy, catheter angiography, or duplex ultrasound
imaging.
For AAA patients, data on the diameter, surgical repair,
and rupture of the aneurysm were obtained. The pres-
ence of aneurysms in other locations in addition to the
abdominal aorta was assessed. Rupture of the AAA was
conﬁrmed using ultrasound imaging or during surgical
repair of the aneurysm.
SAF assessment. SAF as a noninvasive measure of skin
AGEs was assessed using the AGE Reader (Diagnoptics
Technologies BV, Groningen, The Netherlands). This de-
vice uses ultraviolet A light to measure the dermal con-
tent of certain AGEs using their ﬂuorescent properties.
Fig 1. Flowchart of the study inclusion process of patients with abdominal aortic aneurysm (AAA) patients and
controls. CV, Cardiovascular; PAD, peripheral artery disease; ZODIAC, Zwolle Outpatient Diabetes project Inte-
grating Available Care.
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surrounding light and exposed to excitation light with
a wavelength between 300 and 420 nm with a peak of
370 nm.6 Fluorescent AGEs characteristically emit light
of a wavelength between 420 and 600 nmwith a peak of
w440 to 450 nm, whereas reﬂected light is identical to
the excitation light. SAF is calculated as the ratio be-
tween emission light and reﬂected light, multiplied by
100 and expressed in arbitrary units.
Previous studies by Meerwaldt et al6,20 showed a strong
correlation between SAF and skin biopsy specimen con-
tent of several important AGEs, including the ﬂuorescent
AGE pentosidine and two nonﬂuorescent AGEs, N 3-
carboxy-methyl-lysine and N 3-carboxy-ethyl-lysine. The
inner forearm was accepted as the standard and most
accessible location to measure SAF because a validation
study showed a strong correlation between
measurements of the arm and the leg.6 The mean SAF
is calculated from three consecutive measurements
performed automatically by the AGE Reader. An intrain-
dividual variance of 4.5% was shown in an earlier study
with measurements performed on a single day.21
Statistical analysis. Data are shown as mean 6 stan-
dard deviation, median (interquartile range [IQR]), or as
number (%). Characteristics of AAA patients and controls
were compared using the Student independent t-test or
the c2 test. SAF between groups was compared using the
Student independent t-test.
The determinants of SAF in the AAA patients were eval-
uated in a backward multivariable linear regression anal-
ysis. A P value of <.05 was considered statistically
signiﬁcant. To study the association between SAF and
the presence of AAA, a logistic regression analysis was
performed in the complete study group (AAA patients
and controls). Three models were tested: a crude model
with SAF as the sole determinant, an adjusted model
1 with SAF and cardiovascular comorbidity (presence ofCVD and CAD), and an adjusted model 2 with SAF,
cardiovascular comorbidity, and risk factors of AAA
(ie, sex, current smoking, hypertension and use of
lipid-lowering drugs). The logistic regression models
were intrinsically adjusted for the matched variables,
(age and DM). PAD was not included in the models
because the controls were selected on the absence of
PAD. The statistical analyses were performed using
SPSS software version 22.0 (IBM, Armonk, NY).
RESULTS
Characteristics of patients. Of the 268 patients with
AAA who were eligible to participate, 20 were excluded
due to an inﬂammatory (n ¼ 1) or mycotic aneurysm
(n ¼ 1), recent cardiovascular event (n ¼ 2), end-stage
renal disease (n ¼ 2), solid-organ transplantation (n ¼ 2),
or active cancer (n ¼ 12; Fig 1). The remaining 248 AAA
patients were matched for age and presence of DM with
124 controls.
Surgical repair of the aneurysm had been performed in
160 AAA patients (65%), 27 (11%) of which were per-
formed because of rupture of the aneurysm. The median
preoperative diameter of the aneurysm was 60 mm (IQR,
55-70 mm). In the patients who had not undergone sur-
gical repair, the median diameter was 48 mm (IQR,
42-57 mm). The diameter of the aorta was not measured
preoperatively in 26 patients (10%) due to emergency
repair of a ruptured AAA (n ¼ 9) or because the operation
was performed in a different hospital without traceable
information on diameter (n ¼ 17). Median time between
surgery and inclusion date was 3.20 years (IQR, 1.00-
7.39 years). In nine AAA patients (4%), simultaneous an-
eurysms were found in other locations in addition to
the abdominal aorta, comprising the iliac artery (n ¼ 4),
popliteal artery (n ¼ 2), thoracic aorta (n ¼ 1), femoral ar-
tery (n ¼ 1), and carotid artery (n ¼ 1).
Characteristics of the AAA patients and controls are
summarized in Table I. Patients and controls had a
Table I. Baseline characteristics of abdominal aortic aneurysm (AAA) patients and controlsa
Characteristicsb AAA patients (n ¼ 248) Controls (n ¼ 124) P value
Age, years 72.9 6 7.1 73.0 6 7.0 Matched
Male sex 227 (92) 51 (41) <.0001
Current smoker 82 (33) 18 (15) <.0001
Body mass index,c kg/m2 27.2 6 4.3 27.7 6 4.9 NS
DM 41 (17) 21 (17) Matched
Blood pressure
Systolic,d mm Hg 139.1 6 22.1 154.2 6 24.5 <.0001
Diastolic,e mm Hg 78.4 6 13.1 81.4 6 9.9 .013
Hypertension 234 (94) 112 (90) NS
Medication use
Lipid-lowering drugs 181 (73) 35 (28) <.0001
Glucose-lowering drugs 31 (13) .f
Anticoagulant therapy 216 (87) 38 (31) <.0001
eGFR,g mL/min/1.73m2 72.4 6 22.5 68.0 6 17.5 .044
Cardiovascular comorbidity 170 (69) 28 (23) <.0001
CAD 115 (46) 16 (13) <.0001
CVD 42 (17) 17 (14) NS
PAD 77 (31) 0 (0) <.0001
AAA diameters, mm
Patients without surgical repair 48 (42-57) N/A
Patients with surgical repairh 60 (55-70) N/A
Surgical repair of AAA 160 (65) N/A
EVAR 87 (35) N/A
Open repair 73 (29) N/A
Rupture of AAA 27 (11) N/A
Skin autoﬂuorescence, AU 2.89 6 0.63 2.68 6 0.63 .003
AU, Arbitrary units; CAD, coronary artery disease; CVD, cerebrovascular disease; DM, diabetes mellitus; eGFR, estimated glomerular ﬁltration rate; EVAR,
endovascular aneurysm repair; NS, not signiﬁcant; N/A, not applicable; PAD, peripheral artery disease.
aAAA patients and controls were matched 2:1 on age and diabetes.
bData are presented as number of patients (%), mean 6 standard deviation, or median (interquartile range [IQR]).
cData missing for seven patients.
dData missing for ﬁve patients.
eData missing for ﬁve patients.
fData missing for all diabetic controls (n ¼ 21).
gData missing for 11 patients.
hDiameter of AAA before surgery in patients with surgical repair, missing for 26 patients.
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tients and 57-90 years in controls). A higher proportion of
AAA patients were men compared with controls (92% vs
41%; P < .001). DM was present in 17% of the AAA patients
and controls. Occurrence of hypertension did not differ
between groups, but the mean systolic and diastolic
blood pressures were lower in the AAA patient group
than in the control group (P < .0001 and P ¼ .013, respec-
tively). The use of lipid-lowering and anticoagulant drugs
was higher in the AAA patients than in the controls
(P < .0001 for both). CAD and PAD were more common
in AAA patients (P < .0001 for both), but the proportion of
patients with CVD did not differ.
SAF results. SAF was signiﬁcantly higher in AAA
patients vs controls, at 2.89 6 0.63 vs 2.68 6 0.63 arbitraryunits (P ¼ .003; Table I; Fig 2). Within the AAA patients,
SAF was higher in the patients with PAD than in the
patients without PAD (P ¼ .01 by univariable analysis;
Fig 2). In a multivariable analysis of SAF, PAD remained a
signiﬁcant determinant (Table II).
In the AAA patients, multivariable linear regression
analysis showed that age, current smoking, hypertension,
eGFR, and PAD were signiﬁcant determinants of SAF
(adjusted R2 ¼ 0.10; Table II). Sex, presence of DM, body
mass index, use of lipid-lowering drugs, anticoagulant
therapy, aortic diameter, and a history of CAD or CVD
were not determinants of SAF in the AAA patients. SAF
levels did not differ between AAA patients who had not
undergone surgical repair, AAA patients who had under-
gone open repair, and AAA patients who had undergone
endovascular repair (Supplementary Fig, online only).
Fig 2. Skin autoﬂuorescence (SAF) in abdominal aortic
aneurysm (AAA) patients, grouped by those with and
without peripheral artery disease (PAD), and controls. Data
are shown in arbitrary units (AU) as the mean 6 standard
error of the mean (range bars). SAF is higher in the total
group of AAA patients than in the controls: 2.89 6 0.04 vs
2.68 6 0.06 (P ¼ .003 by Student independent t-test). SAF
is higher in the AAA patients with PAD than in the AAA
patients without PAD: 3.04 6 0.07 vs 2.83 6 0.05 (P ¼ .01 by
Student independent t-test).
1700 Boersema et al Journal of Vascular Surgery
December 2017Table III reports the result of the logistic regression
models that describe the association between SAF and
the presence of AAA in the total cohort. In the crude
model, SAF was associated with presence of AAA (odds
ratio [OR], 1.74; 95% conﬁdence interval [CI], 1.20-2.51). Af-
ter correction for cardiovascular comorbidity (presence
of CAD or CVD), this association remained signiﬁcant
(OR, 1.78; 95% CI, 1.22-2.60; adjusted model 1). After addi-
tional correction for cardiovascular risk factors in
adjusted model 2 (sex, current smoking, hypertension
and use of lipid-lowering drugs), the association lost its
signiﬁcance (OR, 1.53; 95% CI, 0.94-2.48).
DISCUSSION
This study shows that SAF, as a measure of skin accu-
mulation of AGEs, is increased in patients with AAA
compared with controls. Furthermore, the association
of SAF with AAA disease is independent of the presence
of cardiovascular comorbidity. Still, within the AAA pa-
tients, SAF is closely associated with the presence of
PAD and cardiovascular risk factors.
In several cardiovascular risk groups and disease, such
as renal insufﬁciency, DM, CAD, and PAD, AGE levels are
increased compared with controls.12,15,20,22 The present
study adds AAA patients as a group at high cardiovascu-
lar risk with increased accumulation of AGEs. We foundthe association between SAF and AAA to be indepen-
dent of the presence of CAD and CVD. Earlier studies
on the association between AAA and AGEs are scarce.
A study of eight AAA patients found that AGEs and re-
ceptor for AGE in the aortic wall were increased
compared with ﬁve control samples from a tissue bank
of autopsy materials.23 The same report described a
reduction in the incidence of AAA of 50% in AGE
receptor-knockout mice compared with control mice.23
In contrast, another study of 60 AAA patients with and
without DM showed a lower pentoside content in the
aortic aneurysm wall compared with 26 aortic control
samples with and without DM.24 These differences in
results may be explained by the type of AGEs that were
measured; the latter study only measured the cross-
linking AGE pentosidine, whereas the former study
measured total AGEs content. In our present study, we
used SAF to assess AGEs accumulation, which is corre-
lated to the level of both cross-linking and noncross-
linking AGEs.6 Another explanation for the discrepancy
between the above-mentioned studies may be the
nature of the control samples, since these were taken
from autopsy specimens. Whether accumulation of
AGEs changes after death is unknown. Finally, it is
possible that AGEs exert a double-sided effect on AAA
development. On the one hand, AGEs might stimulate
AAA progression by inducing endothelial dysfunction,
calciﬁcation, loss of compliance, and thrombogenesis.
On the other hand, cross-linking AGEs might have a pro-
tective effect on aneurysm growth through stiffening of
the vascular wall. A recent study in a mouse AAA model
conﬁrmed that homogenous aortic stiffening reduces
aneurysm growth.25
The association we found between SAF and AAA was
partly explained by the presence of cardiovascular risk
factors. Although smoking is a confounding factor in
this analysis, contributing to the generation and accu-
mulation of AGEs while also being a known risk factor
for AAA, this cannot fully negate this interaction.2,26
Therefore, we concluded that SAF in AAA patients is
closely associated with cardiovascular risk factors and
coexisting PAD rather than being solely associated with
the presence of AAA disease. This is in line with earlier re-
ports on increased SAF in PAD patients and increased
SAF in patients with carotid artery disease that was
mainly explained by the coexistence of PAD.12,27
Interestingly, we found a lower prevalence of DM in
AAA patients than in our earlier report on PAD patients.12
This observation is in line with a systematic review
showing a reduced rate of diabetes in AAA patients.28
Possibly, diabetes exhibits a protective effect on AAA
development through increased arterial stiffness
induced by cross-linking of AGEs. In the earlier
mentioned study, AAA samples of diabetic patients
showed a higher level of the cross-linking AGE pentosi-
dine than AAA samples from nondiabetic individuals,
Table III. Association between abdominal aortic aneu-
rysm (AAA) disease and skin autoﬂuorescence (SAF) in the
total study groupa









Male sexb 16.57 8.15-33.70
Current smoking 3.39 1.61-7.13
Hypertension 2.08 0.73-5.95
Use of lipid-lowering drugs 6.94 3.63-13.29
CAD 2.79 1.36-5.75
CVD 0.43 0.19-0.99
CAD, Coronary artery disease; CI, conﬁdence interval; CVD, cerebro-
vascular disease; OR, odds ratio.
aAll crude and adjusted logistic regression models were intrinsically
adjusted for the matched variables of age and diabetes mellitus (DM).
The model did not include peripheral artery disease (PAD) because
controls were selected on the absence of PAD.
bFemale is the reference.
Table II. Multivariable linear regression analysis of skin autoﬂuorescence (SAF) in abdominal aortic aneurysm (AAA) patients
Variablesa Coefﬁcient b SE Standardized coefﬁcient b P value
Age 0.014 0.006 0.157 .019
Current smoking 0.280 0.087 0.215 .001
Hypertension 0.411 0.189 0.141 .031
eGFR (mL/min/1.73m2) 0.004 0.002 0.136 .037
PAD 0.196 0.085 0.148 .022
eGFR, Estimated glomerular ﬁltration rate; PAD, peripheral artery disease; SE, standard error.
aVariables removed from the model were sex, diabetes mellitus (DM), body mass index, anticoagulant therapy, use of lipid-lowering drugs, aortic
diameter, coronary artery disease (CAD) and cerebrovascular disease (CVD).
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further elucidate the possible role of AGEs in the inverse
association of DM with atherosclerotic diseases vs AAA,
we designed the ARTERY (Advanced glycation end-
pRoducts in patients with peripheral arTery disEase
and abdominal aoRtic aneurYsm) study.29 In this study,
AGEs will be measured in aortic and macrovascular
waste material in diabetic and nondiabetic subjects
with AAA or PAD.
Although we showed that SAF is increased in AAA pa-
tients and remains associated with AAA disease after
correction for cardiovascular comorbidity, more research
is needed before conclusions can be drawn about the
clinical implications of SAF measurements in AAA dis-
ease. Speciﬁcally, an investigation of the association be-
tween SAF and mortality, cardiovascular events, and
growth or rupture of the aneurysm in AAA patients is
necessary.15-17 Still, our ﬁndings contribute to the scarceknowledge available on AGEs accumulation in AAA
disease.
Our study has several limitations. Firstly, the large
proportion of patients who underwent surgical repair of
the AAA before inclusion into the study shows that our
population already had extensive disease. Also, the
proportion of patients with CAD or CVD illustrates wide-
spread atherosclerosis in these patients. Thus, our ﬁnd-
ings may not be representative for earlier stages of AAA.
Secondly, our controls were selected on the absence of
a history and symptoms of AAA or PAD, whereas a pro-
portion of our AAA patients did have concurrent PAD.
Therefore, the comparison of SAF between AAA patients
and controls could not be corrected for the presence of
PAD. However, our multivariable linear regression anal-
ysis of SAF in the AAA patients showed that PAD is an
important determinant. Although it is possible that a
small proportion of our control subjects had undiscov-
ered AAA or PAD disease, this would lead to an underes-
timation of the effect of SAF on AAA presence rather
than an overestimation.
Thirdly, the cross-sectional design of this study did not
permit conclusions to be drawn about the causality of
the observed associations.
Fourthly, a limitation of the applicability of the AGE
Reader is that it can only be used on individuals with
skin pigmentation up to Fitzpatrick type V. In skin with
higher pigmentation, excitation and emission light are
both absorbed excessively by melanin, resulting in inac-
curate SAF measurements.
Finally, levels of AGEs were only assessed by SAF and
not directly in vascular tissues. The association between
SAF and AGE content of human blood vessels has been
investigated in patients with CAD, showing that SAF is
correlated with the AGE content of cardiac tissue and
venous bypass graft material.8,9 This grants probability
to the possible association between SAF and AGEs in
the human arterial wall in AAA patients.
CONCLUSIONS
SAF, as a noninvasive assessment of skin accumulation
of AGEs, is increased in patients with AAA compared
with controls, independent of cardiovascular comorbidity.
1702 Boersema et al Journal of Vascular Surgery
December 2017Still, within theAAApatients, SAF is closely associatedwith
the presence of PAD and cardiovascular risk factors. These
ﬁndings suggest that accumulation of AGEs is increased
in AAA patients, partly explained by presence of wide-
spread atherosclerosis.
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Supplementary Fig (online only). Skin autoﬂuorescence
(SAF) in abdominal aortic aneurysm (AAA) patients
grouped by those who have not undergone surgical repair,
those who have undergone open repair, or endovascular
repair (EVAR), and controls. Data for arbitrary units (AU) are
shown as mean 6 standard error of the mean (range bars).
The gray area illustrates the mean 6 standard error of the
mean SAF in the control group.
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